CN101426796A - 用于治疗神经变性病症的美立霉素(meridamycin)类似物 - Google Patents

用于治疗神经变性病症的美立霉素(meridamycin)类似物 Download PDF

Info

Publication number
CN101426796A
CN101426796A CNA2007800078343A CN200780007834A CN101426796A CN 101426796 A CN101426796 A CN 101426796A CN A2007800078343 A CNA2007800078343 A CN A2007800078343A CN 200780007834 A CN200780007834 A CN 200780007834A CN 101426796 A CN101426796 A CN 101426796A
Authority
CN
China
Prior art keywords
compound
alkyl
substituted
group
following structure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800078343A
Other languages
English (en)
Chinese (zh)
Inventor
埃德蒙·易德里斯·格拉齐亚尼
凯文·蓬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of CN101426796A publication Critical patent/CN101426796A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CNA2007800078343A 2006-03-07 2007-03-05 用于治疗神经变性病症的美立霉素(meridamycin)类似物 Pending CN101426796A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77994006P 2006-03-07 2006-03-07
US60/779,940 2006-03-07

Publications (1)

Publication Number Publication Date
CN101426796A true CN101426796A (zh) 2009-05-06

Family

ID=38289934

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800078343A Pending CN101426796A (zh) 2006-03-07 2007-03-05 用于治疗神经变性病症的美立霉素(meridamycin)类似物

Country Status (19)

Country Link
US (1) US7745457B2 (enExample)
EP (1) EP1991551A1 (enExample)
JP (1) JP2009529049A (enExample)
KR (1) KR20080099317A (enExample)
CN (1) CN101426796A (enExample)
AR (1) AR059738A1 (enExample)
AU (1) AU2007223962A1 (enExample)
BR (1) BRPI0708611A2 (enExample)
CA (1) CA2643350A1 (enExample)
CR (1) CR10272A (enExample)
EC (1) ECSP088718A (enExample)
IL (1) IL193414A0 (enExample)
MX (1) MX2008011312A (enExample)
NO (1) NO20083695L (enExample)
PE (1) PE20081550A1 (enExample)
RU (1) RU2008132779A (enExample)
TW (1) TW200804400A (enExample)
WO (1) WO2007103347A1 (enExample)
ZA (1) ZA200807678B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1828203A2 (en) * 2004-12-20 2007-09-05 Wyeth Rapamycin derivatives and the uses thereof in the treatment of neurological disorders
RU2394036C2 (ru) * 2004-12-20 2010-07-10 Вайет Аналоги рапамицина и их применение при лечении неврологических, пролиферативных и воспалительных заболеваний

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9302016D0 (en) 1993-02-02 1993-03-17 Sandoz Ltd Compounds
GB9318144D0 (en) 1993-09-01 1993-10-20 Sandoz Ltd Organic compounds
EP0729471A1 (en) 1993-11-19 1996-09-04 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US20050197356A1 (en) * 2004-03-02 2005-09-08 Wyeth Non-immunosuppressive immunophilin ligands as neuroprotective and/or neuroregenerative agents
BRPI0508224A (pt) 2004-03-02 2007-07-17 Wyeth Corp composto ou um sal farmaceuticamente aceitável do mesmo, cepa de actinomiceto, isolado de uma cepa, métodos para a produção de um macrolìdeo e de um composto, produto, composição, métodos de tratamento de um mamìfero e de um distúrbio neurológico, e, uso de um composto
JP2008501342A (ja) 2004-06-03 2008-01-24 ワイス 複合ポリケチドを生成するための生合成遺伝子クラスター
US7595187B2 (en) * 2004-11-12 2009-09-29 Wyeth Elaiophylin biosynthetic gene cluster
EP1828203A2 (en) 2004-12-20 2007-09-05 Wyeth Rapamycin derivatives and the uses thereof in the treatment of neurological disorders
RU2394036C2 (ru) 2004-12-20 2010-07-10 Вайет Аналоги рапамицина и их применение при лечении неврологических, пролиферативных и воспалительных заболеваний

Also Published As

Publication number Publication date
ZA200807678B (en) 2009-08-26
US7745457B2 (en) 2010-06-29
AU2007223962A1 (en) 2007-09-13
KR20080099317A (ko) 2008-11-12
RU2008132779A (ru) 2010-04-20
EP1991551A1 (en) 2008-11-19
CA2643350A1 (en) 2007-09-13
CR10272A (es) 2008-10-03
MX2008011312A (es) 2008-09-12
US20070213525A1 (en) 2007-09-13
WO2007103347A1 (en) 2007-09-13
ECSP088718A (es) 2008-10-31
BRPI0708611A2 (pt) 2011-06-07
TW200804400A (en) 2008-01-16
NO20083695L (no) 2008-10-03
PE20081550A1 (es) 2008-12-31
IL193414A0 (en) 2009-05-04
AR059738A1 (es) 2008-04-23
JP2009529049A (ja) 2009-08-13

Similar Documents

Publication Publication Date Title
EP3921320B1 (en) Imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivatives as tlr7 agonist
EP2774926B1 (en) Morphinan derivative
EP2693876B1 (en) Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds
JP4196829B2 (ja) ５，８，１４−トリアザテトラシクロ［１０．３．１．０２，１１．０４，９］−ヘキサデカ−２（１１），３，５，７，９−ペンタエンのコハク酸塩およびその医薬組成物
US8710216B2 (en) Organic compounds
HUT77938A (hu) 7-Azabiciklo[2,2,1]-heptán- és -heptén-származékok és kolinerg receptor ligandumként történő alkalmazásuk
WO2016131381A1 (en) Fused-ring compounds, pharmaceutical composition and uses thereof
JP2009507816A (ja) 抗ウィルス薬としての四環式インドール誘導体
WO2018103626A1 (zh) 一类水溶性别孕烯醇酮衍生物及其用途
EP4353724A1 (en) Compound as cdk kinase inhibitor and use thereof
JP7833486B2 (ja) 置換されるカルバメート大環状化合物および関連のある治療方法
KR101545068B1 (ko) Ｃｄｄｏ 에틸 에스테르의 다형체 및 이의 용도
AU2020229920B2 (en) Acryloyl-containing nuclear transport regulator and uses thereof
EP4023649A1 (en) Androgen receptor binding bifunctional molecules
US7745457B2 (en) Meridamycin analogues for the treatment of neurodegenerative disorders
CN112118891B (zh) 作为流感病毒复制抑制剂的稠和多环吡啶酮化合物
EP3935059B1 (en) Modulators of ampa receptor signaling
KR100255619B1 (ko) 신규한 피페리딘 유도체 및 이의 제조방법
Tu et al. Facile synthesis of indole-or benzofuran-fused benzo [a] carbazole-1, 4-diones using a tandem two-step reaction sequence
Rathnayake et al. An asymmetric (3+ 2) cycloaddition/ring-expansion sequence towards lysergic acid
US9771325B2 (en) Tricyclic compounds and preparation thereof
CN120192247A (zh) 取代n-(4-三氟甲基)-2-氰基巴豆酰胺化合物及其制备方法、药物组合及用途
CN119866332A (zh) 铁死亡抑制剂-吩噁嗪乙酰胺
HK40022836B (en) Macrocyclic compound as a wee1 inhibitor and applications thereof
HK40032676A (en) Fused polycyclic pyridone compounds as influenza virus replication inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090506